Ocugen's European Buildout Meets a Financing Overhang: FDA Green Light for OCU410 as Cash Runway Extends to 2028

Ocugen names Jolanda Crombach to lead a new Amsterdam-based European subsidiary as Phase 3 programs progress, but dilution risk weighs on the stock.

Ocugen is pressing ahead on two fronts at once — assembling a European commercial and regulatory footprint while its pipeline clears key US milestones — yet the stock market continues to greet each operational step with caution, weighed down by an unresolved question over future share issuance.

The company this week confirmed that Jolanda Crombach will lead a newly established European subsidiary headquartered in Amsterdam. Her mandate is tightly defined: build out regional operations to shepherd regulatory filings, the Phase 3 programs — including the candidate OCU410 — and a potential future commercial launch across Europe.

That appointment lands alongside a busy calendar of scientific and investor engagement. Ocugen has lined up participation at medical gatherings including the 26th Euretina Congress and the annual meeting of the American Academy of Ophthalmology. On the business side, management will take part in two investor and industry conferences in October, among them the Cell & Gene Meeting on the Mesa.

Clinical Momentum and the Numbers Behind It

The pipeline news has been concrete. The US Food and Drug Administration has granted clearance for the Phase 3 study of OCU410, while the Phase 3 trial of OCU400 has now completed full patient enrollment. Ocugen has flagged major data readouts from all three of its Phase 3 programs for 2027 and 2028 — a horizon that keeps the story firmly in the future tense.

The financial picture accompanying those advances is mixed. In the second quarter of 2026, Ocugen posted a net loss of $0.07 per share, wider than the $0.05 per-share deficit recorded in the same period a year earlier. Total operating expenses climbed to $17.9 million from $15.2 million in the prior-year quarter, reflecting the persistent cost of developing the company's therapeutic candidates. Research and development accounted for $10.7 million of that total, with general and administrative costs at $7.2 million.

Offsetting some of that burn, Ocugen reported a meaningful extension of its financial runway. As of June 30, 2026, cash, cash equivalents and restricted cash stood at $100.4 million. A convertible note financing totaling $130 million, according to the company, pushes its liquidity horizon into 2028.

A Stock Caught Between Ambition and Dilution Risk

None of this has translated into market enthusiasm. In Wednesday's session the shares came under pressure, shedding 2.4% to close at €0.9060. Market watchers pointed to no specific company or sector catalyst for the move. A day later the stock traded at €0.9210, up 1.7%, but still far below its 52-week high of €2.35. Year to date, the equity is down 28%.

The drag is structural rather than operational. A pending shareholder vote on expanding the share count hangs over the stock as a documented overhang. Until investors know the scale and terms of any additional equity that could be created, they are pricing in dilution risk — and that calculation is powerful enough to blunt even regulatory wins.

For shareholders, the setup remains a split screen: Ocugen is advancing its Phase 3 clinical programs and building out European infrastructure, but without final clarity on the financing side, even partial regulatory victories run into the market's skepticism.